AI targeting is helping us to better identify new nutra contacts
The Informa Markets team recently spoke with Tom Ongena, sales director Europe at Sirio Europe about his expectations for the first ever CPHI Festival of Pharma, what he is seeing in the industry and how the CDMO is approaching the virtual event.
Can you give us your early thoughts on the Festival of Pharma?
It’s a completely new approach for both ourselves and our customers, but already I think you can see the industry is adapting. At Sirio Europe my teams and I are all really excited for the launch of the CPHI Festival of Pharma, it’s a tremendous opportunity for us to meet with customers and potential leads. In fact, unusually in the pandemic [with many industries suffering], both nutraceutical and pharma industries have remained very strong. We have seen good demand for products over the last six months, with immunity formulations obviously proving very, very popular.
Yet, despite the demand, we are limited in how we can meet and discuss options with customers. So, we have to reimagine the art of the possible and look for new ways to keep our brand front of mind for customers, and new ways to discuss our new offerings. One element of the CPHI Festival of Pharma that has already proved very successful is the unique AI-driven matchmaking tool they have provided, it’s been a great success and allowed us to arrange much more targeted meetings in advance.
Whereas previously at ‘in person’ events we have traditionally relied upon footfall; so it’s always been very reactive in the past. But here we have had a much better chance to proactively plan our schedules and think out whom we want to speak with. The ability to target our potential leads more prescriptively is a big improvement and we would be keen to see the tool incorporated at all future events once we can travel again.
Who are you looking to speak with and what will you be discussing?
Our core targets remain the same and one thing I like about the festival is that with the two weeks, we do have a good deal of time to really plan for meetings and hopefully engage customers in greater depth. But I think the key point we have taken from other digital events that we attended earlier in the year is to really engage as much as you can in the event. Contact as many people in advance as you can, really explore how many people you can meet with, and I think as the event opens, we will see another glut of registrations as people can make a really late decision on going.
We have three main areas we are looking to promote – an update on new innovations, particularly our probiotic softgel (combined with omega 3), vegetarian softgel and enteric-coated softgel. The vegetarian softgel is a big change for our European customers as we are transferring in the technology from our mother company Sirio, which gives them the option of having vegetarian softgels made in Europe.
More generally, we are also seeing a big interest in the sustainability of manufacturing and the holistic approach to how we ensure nutraceuticals are produced in an environmentally conscious manner. So we will be speaking with our partners and leads about some of the green manufacturing processes we have implemented at our sites, as well as consumer preferences for clean label, plant-based and organic products.
What are your goals for the Festival of Pharma?
Market penetration and market awareness – these are things we absolutely hope to build on. We need to try and make sure the market knows what Sirio and Ayanda do, what we offer. The objective is to ultimately gain new customers, which is no different to when we would attend CPHI Worldwide. Digital events like the Festival of Pharma are still absolutely essential in helping us build a profile in the industry, as a global nutra CDMO, and tell our stories directly to our customers.
Related News
-
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News CPHI Podcast Series: AI transforming pharma manufacturing
This episode explores how AI is revolutionising the pharmaceutical industry, from "smart factories" to seamless supply chain integration, and discuss the transformative advancements shaping the next decade.
-
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development.
-
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma.